Although beta-secretase (BACE1) expression and its enzymatic activity were reported to increase in most sporadic AD patients, APP full-length protein and γ-secretase proteolytic activity remained unchanged (compared to non-dementia controls) [37,38]. This evidence concerns the gene BACE1 and Alzheimer disease.